Clinical Context
A 52-year-old female kidney transplant recipient presents to the outpatient infusion clinic for maintenance immunosuppression with intravenous belatacept. The patient previously received induction therapy and has demonstrated early signs of calcineurin inhibitor–related nephrotoxicity, so the transplant team transitioned her to belatacept to preserve graft function. The clinic nurse verifies identity, reviews the patient’s weight and recent labs (including serum creatinine and complete blood count), confirms no active infections or recent vaccinations that would contraindicate therapy, and prepares the dose using J0485 (injection, belatacept, 1 mg) multiplied by the required milligram dose. A renal transplant specialist (nephrologist) documents the medical necessity and treatment plan; the infusion is administered via peripheral IV over the recommended infusion time with monitoring for infusion reactions. Post-infusion, the patient is observed for the institution’s standard monitoring period, counseled on infection precautions, and scheduled for the next belatacept dosing visit per the regimen (monthly maintenance or as clinically indicated). Documentation includes indication, dose (number of milligrams and units of J0485 billed), lot number, route, site, start/stop times, and any adverse events.